Abstract
We have investigated the expression of two estrogen receptor beta (ERbeta) isoforms, ERbeta1 and ERbeta5, which activate gene transcription independent of estrogen or growth factors, in ERalpha-negative breast cancer tissues. We report here, for the first time, that ERalpha-negative tissues express significant levels of ERbeta1 and ERbeta5, and their expression levels are not different from levels in ERalpha positive tumors. However, significant differences exist between the two racial groups, African American and Caucasian, in that the patients from the former group express higher levels of ERbeta1 and ERbeta5 but not ERalpha. These two transcription factors could be potential molecular targets for designing chemopreventive drugs to treat ERalpha-negative breast cancers.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Black or African American / genetics
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / ethnology
-
Breast Neoplasms / genetics*
-
Estrogen Receptor alpha / genetics*
-
Estrogen Receptor alpha / metabolism
-
Estrogen Receptor beta / genetics
-
Estrogen Receptor beta / metabolism
-
Estrogens / physiology
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Expression Regulation, Neoplastic / genetics*
-
Humans
-
Immunohistochemistry
-
Protein Isoforms / genetics
-
Protein Isoforms / metabolism
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Transcription Factors / genetics
-
Transcription Factors / metabolism
-
White People / genetics
Substances
-
Antineoplastic Agents
-
Estrogen Receptor alpha
-
Estrogen Receptor beta
-
Estrogens
-
Protein Isoforms
-
RNA, Messenger
-
Transcription Factors